A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study (Q34329486)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study (English)

1 reference

Europe PubMed Central

1 August 2017

object named as

Irina Barykina

5

0 references

author name string

Weiwei Zhang

1

1 reference

Europe PubMed Central

1 August 2017

Dongjun Kim

2

1 reference

Europe PubMed Central

1 August 2017

Elizabeth Philip

3

1 reference

Europe PubMed Central

1 August 2017

Zahid Miyan

4

1 reference

Europe PubMed Central

1 August 2017

Birgit Schmidt

6

1 reference

Europe PubMed Central

1 August 2017

Herbert Stein

7

1 reference

Europe PubMed Central

1 August 2017

Gluco VIP study

8

1 reference

Europe PubMed Central

1 August 2017

publication date

1 April 2013

1 reference

Europe PubMed Central

1 August 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

1 August 2017

33

1 reference

Europe PubMed Central

1 August 2017

4

1 reference

Europe PubMed Central

1 August 2017

263-274

1 reference

Europe PubMed Central

1 August 2017

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Postprandial glucose regulation and diabetic complications

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Standards of medical care in diabetes--2011.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Intensive glycemic control in the ACCORD and ADVANCE trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Risk of Hypoglycaemia with Oral Antidiabetic Agents in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0063-3

21 January 2018

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The burden of mortality attributable to diabetes: realistic estimates for the year 2000

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Diabetes Federation: a consensus on Type 2 diabetes prevention

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contribution of postprandial glucose to chronic hyperglycaemia: from the "glucose triad" to the trilogy of "sevens".

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-013-0063-3

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34329486&oldid=1547285001"